Q2 EPS Estimate for Allogene Therapeutics Lifted by Analyst

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Investment analysts at William Blair upped their Q2 2025 EPS estimates for Allogene Therapeutics in a research note issued to investors on Wednesday, May 14th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.26) for the quarter, up from their previous estimate of ($0.30). The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. William Blair also issued estimates for Allogene Therapeutics' Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.98) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.89) EPS.

ALLO has been the subject of several other research reports. Oppenheimer lowered their price objective on shares of Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating for the company in a research note on Wednesday, May 14th. Truist Financial lowered their price objective on shares of Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Canaccord Genuity Group reiterated a "buy" rating and issued a $14.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 14th. Piper Sandler decreased their price target on shares of Allogene Therapeutics from $9.00 to $7.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Finally, HC Wainwright decreased their price target on shares of Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $8.44.

Allogene Therapeutics Price Performance

Shares of NASDAQ ALLO traded down $0.03 during midday trading on Monday, hitting $1.06. The company's stock had a trading volume of 2,853,612 shares, compared to its average volume of 3,333,691. The business's fifty day simple moving average is $1.41 and its two-hundred day simple moving average is $1.86. Allogene Therapeutics has a 1 year low of $0.86 and a 1 year high of $3.78. The firm has a market capitalization of $231.85 million, a price-to-earnings ratio of -0.68 and a beta of 0.60.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.28) EPS for the quarter, meeting the consensus estimate of ($0.28).

Insiders Place Their Bets

In other Allogene Therapeutics news, CEO David D. Chang sold 46,668 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the sale, the chief executive officer now owns 5,276,569 shares of the company's stock, valued at approximately $10,342,075.24. This trade represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 61,757 shares of company stock valued at $115,873. 13.20% of the stock is owned by corporate insiders.

Institutional Trading of Allogene Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC raised its holdings in Allogene Therapeutics by 578.7% during the first quarter. Jane Street Group LLC now owns 1,116,681 shares of the company's stock worth $1,630,000 after purchasing an additional 952,158 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Allogene Therapeutics by 177.9% during the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company's stock worth $8,547,000 after purchasing an additional 3,747,397 shares in the last quarter. Curi RMB Capital LLC raised its holdings in Allogene Therapeutics by 31.0% during the first quarter. Curi RMB Capital LLC now owns 195,890 shares of the company's stock worth $286,000 after purchasing an additional 46,313 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Allogene Therapeutics during the first quarter worth approximately $85,000. Finally, Frazier Life Sciences Management L.P. increased its holdings in shares of Allogene Therapeutics by 34.9% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 3,868,750 shares of the company's stock valued at $5,648,000 after acquiring an additional 1,001,000 shares during the period. Institutional investors and hedge funds own 83.63% of the company's stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).